Safety and acceptability with the use of a contraceptive vaginal ring after surgical or medical abortion

doi:10.1016/j.contraception.2007.01.009

Contraception

Volume 75, Issue 5, May 2007, Pages 367-371

https://doi.org/10.1016/j.contraception.2007.01.009 Get rights and content

Abstract

Objective

The study was conducted to determine if a contraceptive vaginal ring (CVR) is a safe and acceptable method of contraception when used in the proximate postabortion period following first-trimester surgical or medical abortion.

Methods

A CVR was inserted within 1 week following a medical or surgical abortion. Participants were followed up for 3 months to determine safety and acceptability. Safety was measured by the absence of signs of infection or serious adverse events. Acceptability was assessed by the CVR satisfaction survey, completed at the 3-month follow-up visit.

Results

Of 81 participants enrolled in the study, 69 (85%) completed the first-month follow-up visit, and 54 (67%) completed the final 3-month follow-up visit. There were no serious adverse events and no signs of infection on physical exam. Most adverse events were mild and not specifically related to the CVR. Related adverse events were those commonly associated with hormonal contraception use. Eighty-nine percent of participants chose to continue the CVR as their birth control method.

Conclusion

The CVR is potentially safe and has high acceptability when used in the proximate postabortion period following a first-trimester abortion.

Introduction

Nearly half of all pregnancies among women in the United States are unintended, and of these, nearly 50% result in abortion [1]. Women undergoing elective abortion are at an elevated risk for repeat unplanned pregnancy and abortion [2], most often due to ineffective contraceptive practices such as poor compliance [3]. Clearly, providing safe, effective and acceptable contraception following an abortion is an integral part of quality reproductive healthcare.

Hormonal contraception is efficacious if it can be initiated within a week following pregnancy termination [4]. The theoretic high efficacy of hormonal contraception is obviously decreased by imperfect use or lack of compliance [5]. Alternative delivery systems for hormonal contraception may reduce the rate of noncompliance by eliminating the need to take a daily pill. Such an option is the contraceptive vaginal ring (CVR). The CVR (NuvaRing, Organon USA, Roseland, NJ, USA) is a highly effective contraceptive agent when used in a 3-week treatment and 1-week removal schedule [6]. Prior studies of women using this CVR have shown excellent compliance [7], [8], thus reducing the number of unintended pregnancies and, therefore, the need for voluntary termination of an unplanned pregnancy.

This CVR has been approved for use in postabortion patients according to the product labeling [9], yet, specific published data demonstrating safety and tolerability are lacking. Some healthcare providers, without supporting data, have been reluctant to allow patients to douche or insert anything vaginally during the first week following a dilatation and curettage or abortion, in an attempt to reduce contamination and possible ascending infection. However, there is no reason why a CVR cannot be utilized at this time. There is also a lack of data concerning the acceptability of CVR use in the proximate postabortion period.

Due to paucity of data, the present study was undertaken in order to provide an understanding of the safety and acceptability of CVR among women who select this contraceptive method within 1 week following a first-trimester surgical or medical abortion.

Section snippets

Materials and methods

This was an open-label, single-center, nonrandomized study approved by the Western Internal Review Board. All participants provided informed written consent. A total of 81 participants were recruited from women seeking first-trimester medical or surgical abortion at Planned Parenthood of Houston and Southeast Texas. Inclusion criteria were (1) being within 5 days of a surgical abortion or within 7 days of mifepristone for a medical abortion, (2) a desire for contraception, (3) a willingness to

Results

Participants were enrolled between January 2004 and July 2004. Of the 81 participants who were enrolled in the study, 69 (85%) completed the first-month follow-up visit, and 54 (67%) completed the final visit of the study. The mean age of participants was 25 (S.D., 5) with 51% Caucasian, 24% Hispanic, 14% African American, 2% Asian and 9% others. All participants had one or more prior abortions. Race/ethnicity, age and number of prior abortions were similar in the completer and discontinuer

Discussion

The present study is the first report of the safety and acceptability of using the CVR following voluntary first-trimester surgical and medical abortion. Adverse events were mild and were those commonly associated with hormonal contraceptive use. The 46% rate of CVR-related AEs observed in the present study compares favorably with the 40% rate previously published for nonabortion cohorts [11]. Our incidence of CVR-related headache (19%), nausea (7%), breast tenderness (2%) and vaginitis (4%) is

References (14)

T.O. Dieben et al.
Efficacy, cycle control, and user acceptability of a novel combined contraceptive vaginal ring
Obstet Gynecol
(2002)
A. Novak et al.
The combined contraceptive ring, NuvaRing: an international study of user acceptability
Contraception
(2003)
L.B. Finer et al.
Disparities in rates of unintended pregnancy in the United States, 1994 and 2001
Perspect Sex Reprod Health
(2006)
F.E. Skjeldestad
The incidence of repeat induced abortion — a prospective cohort study
Acta Obstet Gynecol Scand
(1994)
M. Garg et al.
Peri-abortion contraceptive care: can we reduce the incidence of repeat abortions?
J Fam Plann Reprod Health Care
(2001)
R. Lesnewski et al.
Initiating hormonal contraception
Am Fam Physician
(2006)
L. Potter et al.
Measuring compliance among oral contraceptive users
Fam Plann Perspect
(1996)

There are more references available in the full text version of this article.

Cited by (30)

Contraceptive plans and purchase after an induced abortion: A nationwide register study from Finland
2024, Contraception
To examine the types of hormonal contraceptive methods chosen at the time of the abortion, and how they correspond to post-abortion hormonal contraceptive purchase.
This was a prospective register-based study. We identified the present cohort of 8428 women undergoing induced abortion between July 1, 2017 and December 31, 2018, using the Prescription Centre, Social Insurance Institution database and the Finnish National Register of Induced Abortions. From the Register of Induced Abortions, we gathered information on planned post-abortion contraception. The redeemed prescriptions of hormonal contraception were identified from the Prescription Centre until December 31, 2019. We analyzed the hormonal contraceptive methods planned at the time of the abortion, and how they corresponded to hormonal contraceptive purchase during the 1-year follow-up. We also assessed factors (age, socioeconomic status, education, civil status, and reproductive history) affecting post-abortion contraceptive purchase by using Poisson regression models.
At the time of the abortion, 83% (n = 7023) of the women were planning to start using hormonal contraception. Planning any hormonal contraception at the time of the abortion was associated with a higher probability to purchase hormonal contraception after the abortion (incidence rate ratio [IRR] 2.30, 95% confidence intervals [CI] 2.07–2.55), especially in cases of the vaginal ring (IRR 42.66, 95% CI 33.89–53.71) and contraceptive patch (IRR 156.33, 95% CI 111.31–219.55). The following variables were associated with lower incidence rates for purchasing hormonal contraception after the abortion: educational level of bachelor at the highest or missing information on education, civil status as married or divorced, and history of delivery or induced abortion.
The majority of women undergoing abortion plan to use hormonal contraceptive method for post-abortion contraception. Planning any hormonal contraceptive method at the time of an induced abortion is an important predictor of purchasing the method within the year after the abortion.
Hormonal contraceptive purchase after an abortion is associated with pre-abortion contraceptive planning. Many background factors for not purchasing hormonal contraception can be identified, which may guide counseling dedicated to these groups.
Vaginal ring acceptability: A systematic review and meta-analysis of vaginal ring experiences from around the world
2022, Contraception
The vaginal ring (ring) is a female-initiated, long-acting drug delivery system for different indications, including HIV prevention. Our aim was to provide evidence for acceptability of the vaginal ring across indications to support dapivirine and multipurpose prevention technology ring introduction and roll out.
This systematic review and meta-analysis followed PRISMA guidelines. We searched PubMed, Web of Science, Embase, and grey literature for publications reporting favorable ring acceptability and secondary outcomes involving actual ring use (comfort, ease of ring use, ring comfort during sex, expulsions, and vaginal symptoms) or hypothetical acceptability for any indication published January 1, 1970−June 15, 2021. We estimated random-effects pooled prevalence, assessing between-study variation using meta-regression.
Of 2,234 records, we included 123 studies with 40,434 actual and hypothetical ring users. The primary outcome assessment included 50 studies with 60 ring subgroups totaling 19,271 ring users. The favorable acceptability pooled prevalence was 85.6% (95%CI 81.3, 89.0), while hypothetical acceptability among non-ring users was 27.6% (95%CI 17.5, 40.5). In meta-regression, acceptability was higher in menopause (95.4%; 95%CI 88.4, 98.2) compared to contraceptive rings (83.7%; 95%CI 75.6, 89.5). Acceptability was lower in pharmacokinetic studies (50%; 95%CI 22.1, 77.9) compared to RCTs (89.5%; 95%CI 85.8.92.4) and in studies assessing acceptability at ≥12 months (78.5%; 95%CI 66.5, 87.1) versus studies assessing acceptability at <3 months (91.9%; 95%CI 83.7, 96.1). European (90.6%; 95%CI 83.9, 94.7), Asian (97.1%; 95%CI 92.0, 99.0), and multi-region studies (93.5%; 95%CI 84.6, 97.4) reported more favorable acceptability compared to African studies (59.4%; 95%CI 38.3, 77.5). Secondary outcomes were similarly favorable, including ring comfort (92.9%; 95%CI 89.2, 95.4), ease of use (90.9%; 95%CI 86.5, 94.0), and comfort during sex (82.7%; 95%CI 76.4, 87.6). Limitations include inconsistent outcome definitions and unmeasured factors affecting acceptability.
Women who used vaginal rings reported they were acceptable across indications geographic regions and indications. Policy makers should consider the ring as an important option for pregnancy and HIV prevention drug development.
This review found favorable acceptability among vaginal ring users across indications and geographic areas, in contrast to low hypothetical acceptability among non-users. Vaginal rings are an important drug delivery system for pregnancy and HIV preventions, and scale-up should plan to address initial hesitancy among new users.
Society of Family Planning clinical recommendations: contraception after surgical abortion
2019, Contraception
These recommendations present an evidence-based assessment of provision of contraceptives at the time of surgical abortion. Most methods of contraception, including the intrauterine devices (IUD), implant, depot medroxyprogesterone injection, oral contraceptive pill, contraceptive patch, monthly vaginal ring, barrier methods and some permanent methods, can be safely initiated immediately after first- or second-trimester surgical abortion. Provision of postabortion contraceptives, particularly IUDs and implants, substantially reduces subsequent unintended pregnancy. IUD insertion immediately following uterine aspiration is safe. While this may be associated with a higher risk of device expulsion than with interval placement, expulsion rates remain low, and this risk must be weighed against the fact that patients often do not receive their desired IUD at an interval insertion and therefore experience higher rates of subsequent unintended pregnancy. Many patients experience barriers that prevent access to the full spectrum of postabortion contraceptive options, particularly IUDs and implants. Advancements in health-systems-based point-of-care provision and policies are needed to improve comprehensive contraceptive availability following surgical abortion. These recommendations will address clinical considerations for postabortion contraceptive provision and recommend interventions to improve contraceptive access following uterine evacuation.
N<sup>o</sup> 360 - Avortement provoqué: avortement chirurgical et méthodes médicales au deuxième trimestre
2018, Journal of Obstetrics and Gynaecology Canada
Citation Excerpt :
La prise immédiate de COC après un AC n'est associée à aucune augmentation des saignements vaginaux ou des effets secondaires, ni à aucun changement clinique significatif des paramètres de la coagulation comparativement à l'amorce plus tardive ou aux méthodes contraceptives non hormonales412,413. D'après des données limitées, l'insertion d'un anneau vaginal tout de suite après un AP au premier trimestre n'entraînerait aucune augmentation des infections ou d'autres événements nocifs à trois mois414. Un ECR portant sur l'instauration immédiate d'une contraception par timbre n'a montré aucun effet nocif sur les saignements après l'avortement, ni aucune amélioration quant à la poursuite de la méthode après six mois415.
La présente directive clinique examine les données probantes sur l'avortement chirurgical et l'avortement médical au deuxième trimestre, y compris les soins prodigués avant et après l'intervention.
Gynécologues, médecins de famille, infirmières, sages-femmes, résidents et autres fournisseurs de soins de santé qui pratiquent ou enseignent, ou ont l'intention de pratiquer ou d'enseigner, l'avortement provoqué (AP).
Femmes dont la grossesse de premier ou de deuxième trimestre est non désirée ou anormale.
Des recherches ont été menées dans PubMed, Medline et la base de données Cochrane à l'aide des mots-clés « first-trimester surgical abortion », « second-trimester surgical abortion », « second-trimester medical abortion », « dilation and evacuation », « induction abortion », « feticide », « cervical preparation », « cervical dilation » et « abortion complications ». Nous n'avons tenu compte que des revues systématiques, des essais cliniques randomisés, des essais cliniques et des études observationnelles de langue anglaise ou française publiés entre 1979 et juillet 2017. Des directives cliniques nationales et internationales ont été consultées. Nous n'avons pas effectué de recherches dans la littérature grise (non publiée).
La qualité des données probantes a été évaluée au moyen de l'approche GRADE (Grading of Recommendations Assessment, Development and Evaluation). Le résumé des conclusions peut être fourni sur demande.
L'AP est sûr et efficace. Les avantages en surpassent les dommages et les coûts potentiels. Aucun nouveau dommage ou coût direct n'a été associé à la présente directive clinique.
No. 360-Induced Abortion: Surgical Abortion and Second Trimester Medical Methods
2018, Journal of Obstetrics and Gynaecology Canada
Citation Excerpt :
Immediate COC start after SA is not associated with an increase in vaginal bleeding, side effects, or clinically significant changes in coagulation parameters compared with delayed initiation or other non-hormonal contraceptive methods.412,413 Limited evidence on vaginal contraceptive ring used immediately post first trimester IA has demonstrated no increase in infection or other adverse events at 3 months.414 One RCT of immediate contraceptive patch initiation found no adverse effect on post-abortion bleeding and no improvement in method continuation at 6 months.415
This guideline reviews evidence relating to the provision of surgical induced abortion (IA) and second trimester medical abortion, including pre- and post-procedural care.
Gynaecologists, family physicians, nurses, midwives, residents, and other health care providers who currently or intend to provide and/or teach IAs.
Women with an unintended or abnormal first or second trimester pregnancy.
PubMed, Medline, and the Cochrane Database were searched using the key words: first-trimester surgical abortion, second-trimester surgical abortion, second-trimester medical abortion, dilation and evacuation, induction abortion, feticide, cervical preparation, cervical dilation, abortion complications. Results were restricted to English or French systematic reviews, randomized controlled trials, clinical trials, and observational studies published from 1979 to July 2017. National and international clinical practice guidelines were consulted for review. Grey literature was not searched.
The quality of evidence in this document was rated using the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) methodology framework. The summary of findings is available upon request.
IA is safe and effective. The benefits of IA outweigh the potential harms or costs. No new direct harms or costs identified with these guidelines.
Post-abortion contraception
2016, Journal de Gynecologie Obstetrique et Biologie de la Reproduction
Établir des recommandations du Collège national des gynécologues et obstétriciens français (CNGOF) concernant la contraception après interruption volontaire de grossesse (IVG).
Une revue systématique de la littérature concernant la contraception après IVG a été réalisée sur Medline et Cochrane Database entre 1978 et mars 2016, ainsi que la consultation des recommandations des sociétés savantes françaises et étrangères.
Après une IVG, si la femme souhaite une contraception, celle-ci doit être débutée le plus tôt possible car la reprise de l’ovulation est très rapide. Le choix de la contraception doit être fait en accord avec les attentes et le mode de vie de la femme. Une information claire, objective et personnalisée sur tous les moyens de contraception utilisables par la femme devrait lui être délivrée. Les contre-indications de chaque moyen de contraception doivent être respectées. Les méthodes contraceptives réversibles à longue durée d’action, dispositifs intra-utérins et implant, pourraient être privilégiées (grade C) car elles n’engendrent pas de problème d’adhésion et pourraient ainsi mieux prévenir la répétition des IVG (NP3). Le DIU doit être proposé et inséré de manière préférentielle immédiatement au décours d’une IVG instrumentale (grade A), de même que l’implant (grade B). En cas d’IVG médicamenteuse, l’implant peut être inséré à partir du jour de la prise de mifépristone, le DIU dès la confirmation échographique de l’absence de grossesse intra-utérine (grade C).
To establish guidelines of the French National College of Gynecologists and Obstetricians about post-abortion contraception.
A systematic review of the literature about post-abortion contraception was performed on Medline and Cochrane Database between 1978 and March 2016. The guidelines of the French and foreign scientific societies were also consulted.
After an abortion, if the woman wishes to use a contraception, it should be started as soon as possible because of the very early ovulation resumption. The contraception choice must be done in accordance with the woman's expectations and lifestyle. The contraindications of each contraception must be respected. The long-acting reversible contraception, intra-uterine device (IUD) and implant, could be preferred (grade C) as the efficacy is not dependent on compliance. Thus, they could better prevent repeat abortion (LE3). In case of surgical abortion, IUD should be proposed and inserted immediately after the procedure (grade A), as well as the implant (grade B). In case of medical abortion, the implant can be inserted from the day of mifépristone, the IUD after an ultrasound examination confirming the success of the abortion (no continuing pregnancy or retained sac) (grade C).

View all citing articles on Scopus

^☆: This study was an investigator-initiated study supported by an unrestricted educational grant from Organon USA Inc, Roseland, NJ, USA.

View full text

Original research articleSafety and acceptability with the use of a contraceptive vaginal ring after surgical or medical abortion☆

Abstract

Objective

Methods

Results

Conclusion

Introduction

Section snippets

Materials and methods

Results

Discussion

Obstet Gynecol

Contraception

Disparities in rates of unintended pregnancy in the United States, 1994 and 2001

Perspect Sex Reprod Health

The incidence of repeat induced abortion — a prospective cohort study

Acta Obstet Gynecol Scand

Peri-abortion contraceptive care: can we reduce the incidence of repeat abortions?

J Fam Plann Reprod Health Care

Initiating hormonal contraception

Am Fam Physician

Measuring compliance among oral contraceptive users

Fam Plann Perspect

Original research article
Safety and acceptability with the use of a contraceptive vaginal ring after surgical or medical abortion☆